Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals With Hyperlipidemia

Prior treatment

• Concurrent participation in any other weight-loss therapy
• Current use of hypoglycemic or lipid-lowering medications
• Participation in any other clinical trial within one month prior to signing the informed consent form

Other illness

• Diagnosis of acute or severe gastrointestinal disease
• Known allergy to cellulose or wheat
• History of cancer
• Any other condition deemed by the investigator as inappropriate for trial participation

Lab values

• Renal insufficiency, indicated by abnormal serum creatinine levels
• Hepatic impairment, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 × upper limit of normal (ULN), or total bilirubin (TBIL) \>3 × ULN

Other

• Pregnancy, lactation, or planning a pregnancy during the trial period

• Males or females aged 18 to 65 years.
• BMI ≥ 24 kg/m², without severe chronic diseases.
• Not currently using glucose-lowering or lipid-lowering medications.
• Dyslipidemia defined as triglycerides ≥ 1.7 mmol/L or total cholesterol ≥ 5.2 mmol/L.
• No active weight loss or weight gain diet within the past 1 month.
• No special dietary pattern changes (e.g., ketogenic, vegan, high-protein, meal replacement, intermittent fasting) within the past 1 month.
• No use of supplements that may affect polyamine intake (e.g., germ, yeast, fermented extracts, nutritional powders) within the past 2-4 weeks.
• Willing and able to provide signed informed consent.